Sponsored by:
General Motors (GM)
General Electric (GE)
Apple (AAPL)
Deere (DE)
Focus Stocks
Featured Stories
S&P Indices Announces Changes to U.S. Indices
Staples, Inc. Announces First Quarter 2012 Performance
Xerox Broke Support
Are the Bears Taking Control over F5 Networks?
Chico's FAS Reports First Quarter Earnings
HeartWare to Present at the 23rd Annual Piper Jaffray Health Care Conference
Published on Wednesday, 23 November 2011 06:11 Written by TradersHuddle Staff
FRAMINGHAM, Mass. and SYDNEY, Nov. 23, 2011 /PRNewswire/ -- HeartWare International, Inc. (NASDAQ: HTWR - ASX: HIN), a leading innovator of less invasive, miniaturized circulatory support technologies that are revolutionizing the treatment of advanced heart failure, today announced that CEO Doug Godshall is scheduled to present at the 23rd Annual Piper Jaffray Health Care Conference at 11:30 a.m. EST on Wednesday, November 30, 2011. The conference is being held November 29-30, 2011 at The New York Palace in New York City.
A live webcast of the Company's presentation at the conference will be available via a link provided at www.heartware.com. A replay of the webcast will be available for 90 days at the site after the presentation.
About HeartWare International
HeartWare International develops and manufactures miniaturized implantable heart pumps, or ventricular assist devices, to treat Class IIIB / IV patients suffering from advanced heart failure. The HeartWare® Ventricular Assist System features the HVAD® pump, a small full-output circulatory support device (up to 10L/min flow) designed to be implanted next to the heart, avoiding the abdominal surgery generally required to implant competing devices. HeartWare has received CE Marking for the HeartWare System in the European Union and TGA approval in Australia. The device is currently the subject of United States clinical trials for two indications: bridge-to-transplant and destination therapy. For additional information, please visit www.heartware.com.
HeartWare International, Inc. is a member of the Russell 2000® and its securities are publicly traded on The NASDAQ Stock Market and the Australian Securities Exchange.
HEARTWARE, HVAD, MVAD and HeartWare logos are registered trademarks of HeartWare, Inc.
For further information:
Christopher Taylor
HeartWare International, Inc.
Email:
This e-mail address is being protected from spambots. You need JavaScript enabled to view it.
Phone: +1 508 739 0864
SOURCE HeartWare International, Inc.
Related Articles
- HeartWare International Reports First Quarter 2012 Revenue of $26.3 Million; 47% Increase From $18.0 Million in First Quarter 2011
- HeartWare Completes Enrollment In 450-Patient Pivotal Destination Therapy Clinical Trial
- HeartWare Presentation at the Bank of America Merrill Lynch 2012 Health Care Conference to be Webcast
- Heartware Schedules First Quarter Conference Call And Webcast
- FDA Advisory Committee Votes in Favor of HeartWare® Ventricular Assist System as Bridge to Transplant for Patients With End-Stage Heart Failure
- HeartWare Stock Trading Halted Today; FDA Advisory Committee to Review HeartWare® Ventricular Assist System as a Bridge to Heart Transplantation
- HeartWare International Expands Intellectual Property and Technology Portfolio Through Definitive Agreement to Acquire World Heart Corporation for US$8 Million
- HeartWare Receives 54-Patient Allotment From FDA Under Continued Access Protocol for Pivotal U.S. Bridge-to-Transplant Clinical Trial
- HeartWare Presentation At The Barclays Capital 2012 Global Healthcare Conference To Be Webcast
- HeartWare International Reports Fourth Quarter 2011 Revenues of $23.1 Million; Full Year 2011 Revenues of $82.8 Million; 50% Increase From $55.2 Million in 2010
Related Partner Headlines
- Oppenheimer Reiterates Perform Rating, Does Not Set PT for HeartWare - Benzinga
- UPDATE: Piper Jaffray Maintains Neutral Rating, Raises PT for HeartWare International - Benzinga
- UPDATE: Canaccord Genuity Raises HeartWare International's PT - Benzinga
- UPDATE: J.P. Morgan Raises HeartWare International's PT - Benzinga
- Heartware International Stock Hits New 52-Week Low (HTWR) - TheStreet.com
Volatile market? That's when profit potential skyrockets for options traders. Now you can get up to 50 trade opportunities a week from top options experts -- plus much more -- on our exciting new site OptionsProfits.
Try it FREE!
TradersHuddle Search
| Sponsored By:
|
|
Stock Search: |
|
Site Search: Loading
|
Latest Partner Headlines
Stock Market
Loading
